Hologic operates in the highly regulated medical technology industry, focusing on women's health through early detection and treatment. The company develops, manufactures, and supplies premium diagnostics products, medical imaging systems, and surgical products. The industry is characterized by rapid technological change, frequent product introductions, and evolving customer requirements, with significant competition from larger companies such as Roche Diagnostics, Abbott Laboratories, Cepheid, Becton Dickinson, Siemens Healthineers, GE Healthcare, Johnson & Johnson, and Medtronic. Hologic competes across four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, and faces additional competition from alternative treatments like drug therapy and from non-medical technology companies offering alternative tests or therapies.

Hologic's primary competitors include Roche Diagnostics, Abbott Laboratories, and Cepheid in molecular diagnostics; Becton Dickinson in cytology; Siemens Healthineers and GE Healthcare in breast and skeletal health imaging; and Johnson & Johnson and Medtronic in GYN surgical products. The company also competes with a wide range of single-technology companies and local competitors in international markets. Hologic believes its success depends on differentiating through clinical efficacy, ease of use, reliability, accuracy, quality, and cost, and on continued investment in product enhancements and technologies.

Hologic generates revenue through a combination of product sales and service revenues across four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Revenue streams include recurring income from consumables such as molecular diagnostic assays, ThinPrep supplies, and single-use surgical devices, as well as transactional income from capital equipment sales like mammography systems and bone densitometers. Service revenue is generated from service contracts, primarily for digital mammography equipment, and from the company's CLIA-certified laboratory offering Breast Cancer Index and CancerTYPE ID tests. Products are sold through a direct sales force and a network of independent distributors and sales representatives, with end customers including clinical laboratories, hospitals, healthcare providers, and surgeons.

The Diagnostics segment offers a wide range of diagnostic products for screening and diagnosis of human diseases, including molecular diagnostic assays run on the Panther and Panther Fusion systems, the ThinPrep System for cytology, the Genius Digital Diagnostics System with AI algorithm, and the Rapid fFN Test for pre-term birth risk. Key assays include the Aptima family for STDs, HPV, Trichomonas vaginalis, Mycoplasma genitalium, Herpes Simplex viruses, and viral load tests for HBV, HCV, HIV-1, and CMV, as well as assays for respiratory infections, Group B Streptococcus, and gastrointestinal pathogens. The segment also includes the Biotheranostics business offering Breast Cancer Index and CancerTYPE ID laboratory-developed tests. The Breast Health segment provides 3D digital mammography systems (Selenia Dimensions and 3Dimensions), image analysis software (Genius AI Detection, ImageChecker, Quantra), minimally invasive breast biopsy guidance systems (Affirm prone and upright), breast biopsy devices (Brevera, ATEC, Eviva, Celero, Sertera), and surgical products including Magseed marker, Magtrace lymphatic tracer, and Sentimag platform from the Endomag acquisition. The GYN Surgical segment includes the MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Fluent fluid management system, Sonata transcervical radiofrequency ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, CoolSeal vessel sealing portfolio, and JustRight surgical stapler. The Skeletal Health segment offers the Horizon DXA system for bone density and body composition assessment, and the Fluoroscan Insight FD mini C-arm, which is being discontinued effective fiscal 2026.

In fiscal 2025, Hologic recorded tariff expense of $9.5 million ¹ primarily in the fourth quarter, and estimated that if maintained at current levels, the impact of direct tariff costs on a quarterly basis will be approximately $10 million to $14 million ². The company announced in the fourth quarter of fiscal 2025 that it will shut down its Manchester, England facility, which manufactures certain Molecular Diagnostic assays, and transfer production to its San Diego, California facility, with completion expected in the first half of calendar 2026. On October 21, 2025, Hologic entered into a definitive agreement to be acquired by funds managed by Blackstone Inc. and TPG Capital for $76.00 per share ³ in cash, plus a non-tradable contingent value right to receive up to $3.00 per share ⁴ in cash, for total potential consideration of $79.00 per share ⁵ in cash. The transaction is expected to close in the first half of calendar year 2026, subject to stockholder approval, regulatory approvals, and other customary conditions. In fiscal 2025, the company acquired Gynesonics, Inc. in January 2025, which added the Sonata system to the GYN Surgical portfolio. The company also completed the acquisition of Endomagnetics Ltd in fiscal 2024, adding wire-free breast surgery localization and lymphatic tracing solutions.

For fiscal year 2025, total net revenues were $4,030.3 million ⁶, compared to $4,030.1 million ⁷ in fiscal 2024 and $4,030.4 million ⁸ in fiscal 2023. Net income was $478.2 million ⁹ in fiscal 2025, compared to $468.5 million ¹⁰ in fiscal 2024 and $1,170.4 million ¹¹ in fiscal 2023. Diluted earnings per share were $2.05 ¹² in fiscal 2025, compared to $1.97 ¹³ in fiscal 2024 and $4.82 ¹⁴ in fiscal 2023. The company generated operating cash flow of $1,009.5 million ¹⁵ in fiscal 2025, compared to $1,016.7 million ¹⁶ in fiscal 2024. The Diagnostics segment revenue was $1,769.7 million ¹⁷ in fiscal 2025, Breast Health segment revenue was $1,543.3 million ¹⁸, GYN Surgical segment revenue was $579.6 million ¹⁹, and Skeletal Health segment revenue was $137.7 million ²⁰.

A key growth vector is the Genius Digital Diagnostics System, which received FDA marketing clearance for diagnostic use in the U.S. in January 2024 and is CE-marked for diagnostic use in the EU since November 2020. This system combines a new artificial intelligence algorithm with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. Another growth vector is the expansion of the molecular diagnostic assay menu, including the Panther Fusion EBV Quant and BKV Quant assays for transplant monitoring, which are the first quantitative real-time PCR assays on the Panther Fusion system. The company also sees growth opportunities in the international market, where 25.7% ²¹ of fiscal 2025 revenue came from outside the U.S., and in the GYN Surgical segment through the recently acquired Sonata system and Acessa ProVu system for fibroid treatment.

The filing does not contain specific margin or cost outlook figures.

The filing discusses the planned shutdown of the Manchester, England facility, which manufactures certain Molecular Diagnostic assays, with production transfer to the San Diego, California facility expected to be completed in the first half of calendar 2026. The company also noted that it is discontinuing the sale of its Fluoroscan Insight FD systems effective fiscal 2026. The company's manufacturing operations are concentrated in a limited number of facilities, including locations in Costa Rica and England, and the company relies on sole source third-party manufacturers for Panther and Panther Fusion instruments (Stratec SE) and Skeletal Health products (Flextronics Medical Sales and Marketing, LTD).

Research and development expenses were $330.1 million ²² in fiscal 2025, compared to $316.5 million ²³ in fiscal 2024 and $307.0 million ²⁴ in fiscal 2023. Capital expenditures were $103.6 million ²⁵ in fiscal 2025, compared to $103.5 million ²⁶ in fiscal 2024. The company has a share repurchase program; during fiscal 2025, the company repurchased 4,000,000 ²⁷ shares of common stock for $300.0 million ²⁸ under an accelerated share repurchase agreement. As of September 27, 2025, the company had $1,000.0 million ²⁹ remaining under its share repurchase authorization. The company did not pay dividends in fiscal 2025.

The filing identifies several headwinds, including the impact of tariffs; for fiscal 2025, primarily in the fourth quarter, the company recorded tariff expense of $9.5 million ³⁰, and estimated that if maintained at current levels, the impact of direct tariff costs on a quarterly basis will be approximately $10 million to $14 million ³¹. The company faces risks from global supply chain constraints, particularly for semiconductor chips used in Breast Health capital equipment products. The company also faces risks from changes in healthcare reimbursement policies, guidelines from professional societies that may reduce use of products (such as the American Cancer Society's 2015 guidelines recommending mammograms start at age 45 instead of 40 and the 2020 guidelines recommending HPV primary screening over co-testing), and from the ongoing uncertainty regarding macroeconomic conditions, inflation, rising interest rates, and geopolitical issues.

The company faces risks from the proposed acquisition by Blackstone and TPG, including the possibility that the merger may not close in the anticipated timeframe or at all, which could have an adverse effect on the business. The merger agreement restricts the company from taking certain actions without approval, including issuing shares, making acquisitions, incurring capital expenditures outside the budget, and entering into material contracts. If the merger agreement is terminated under certain circumstances, the company may be required to pay a termination fee of $540 million ³² (or $225 million ³³ during the go shop period). The company also faces risks related to the contingent value rights, as there can be no assurance that any payment will be made under the CVR.

Management's message emphasizes the company's focus on women's health through early detection and treatment, with a portfolio spanning diagnostics, medical imaging, and surgical products. The filing highlights the proposed acquisition by Blackstone and TPG as a significant event, with management noting the transaction is expected to close in the first half of calendar year 2026, subject to stockholder and regulatory approvals. Key strategic priorities include continuing to invest in research and development, with R&D spending of $330.1 million ⁴⁰ in fiscal 2025, expanding the molecular diagnostic assay menu, and integrating recent acquisitions such as Gynesonics (adding the Sonata system) and Endomagnetics (adding wire-free localization and lymphatic tracing). Management also emphasizes the importance of the Genius Digital Diagnostics System, which received FDA clearance in January 2024, and the international expansion, with 25.7% ⁴¹ of revenue coming from outside the U.S. in fiscal 2025.

For fiscal year 2025, total net revenues were $4,030.3 million ⁴², essentially flat compared to $4,030.1 million ⁴³ in fiscal 2024 and $4,030.4 million ⁴⁴ in fiscal 2023. Net income was $478.2 million ⁴⁵ in fiscal 2025, compared to $468.5 million ⁴⁶ in fiscal 2024 and $1,170.4 million ⁴⁷ in fiscal 2023. Diluted earnings per share were $2.05 ⁴⁸ in fiscal 2025, compared to $1.97 ⁴⁹ in fiscal 2024 and $4.82 ⁵⁰ in fiscal 2023. Operating income was $1,006.2 million ⁵¹ in fiscal 2025, compared to $1,008.7 million ⁵² in fiscal 2024 and $1,636.2 million ⁵³ in fiscal 2023. The company generated operating cash flow of $1,009.5 million ⁵⁴ in fiscal 2025, compared to $1,016.7 million ⁵⁵ in fiscal 2024. As of September 27, 2025, cash, cash equivalents, and restricted cash totaled $2,183.8 million ⁵⁶, compared to $2,443.7 million ⁵⁷ as of September 28, 2024. Total debt was $2,652.4 million ⁵⁸ as of September 27, 2025, compared to $2,651.2 million ⁵⁹ as of September 28, 2024. The Diagnostics segment revenue was $1,769.7 million ⁶⁰ in fiscal 2025, Breast Health segment revenue was $1,543.3 million ⁶¹, GYN Surgical segment revenue was $579.6 million ⁶², and Skeletal Health segment revenue was $137.7 million ⁶³. Fiscal 2023 net income included a significant benefit from a $1,170.4 million ⁶⁴ figure that was boosted by a $1,170.4 million ⁶⁵ net income, which was significantly higher than fiscal 2025 and 2024 due to lower impairment charges and other items. The company recorded impairment charges of $19.4 million ⁶⁶ in fiscal 2025, $25.4 million ⁶⁷ in fiscal 2024, and $19.4 million ⁶⁸ in fiscal 2023 related to intangible assets and other assets.

The proposed acquisition by Blackstone and TPG presents material risks, including the possibility that the merger may not close, which could result in a termination fee of $540 million ³⁴ (or $225 million ³⁵ during the go shop period) and significant transaction costs. The company faces risks from tariffs, having recorded $9.5 million ³⁶ in tariff expense in fiscal 2025, with an estimated quarterly impact of $10 million to $14 million ³⁷ if current levels are maintained. The Diagnostics segment depends on a limited number of customers, with two customers accounting for 13.6% ³⁸ and 10.8% ³⁹ of Diagnostics segment revenue in fiscal 2025, and the loss of either could significantly reduce revenues. The company relies on sole source third-party manufacturers for Panther instruments (Stratec SE) and Skeletal Health products (Flextronics), and on a single supplier (Roche) for key raw materials for certain NAT diagnostic assays, creating supply chain concentration risk. Changes in healthcare reimbursement policies and guidelines from organizations such as the American Cancer Society, which recommended HPV primary screening over co-testing in July 2020 and less frequent mammograms starting at age 45 in October 2015, could reduce demand for the company's products.